Partial
Not Aligned
Patient Risk:
High
Summary
The AI response includes multiple claims that are not supported by the provided FDA label excerpts and several claims that appear inconsistent with the specific product labeling (extended-release formulation dosing and dosing limits). Some safety statements broadly match label warnings (e.g., seizures, respiratory depression), but overall alignment is limited by dosage/administration errors and unsupported content.
Category Scores
Accurate Statements
Tramadol hydrochloride works by binding to specific receptors in the brain and spinal cord involved in pain perception.
12.1 Mechanism of Action (opioid agonist; mu-opioid receptor binding of parent and M1).
Tramadol hydrochloride has a dual mechanism of action affecting opioid receptors.
12.1 Mechanism of Action (opioid agonist and inhibitor of reuptake of norepinephrine and serotonin).
Tramadol hydrochloride affects the reuptake of certain neurotransmitters including serotonin.
12.1 Mechanism of Action (inhibitor of reuptake of norepinephrine and serotonin).
Tramadol hydrochloride affects the reuptake of certain neurotransmitters including norepinephrine.
12.1 Mechanism of Action (inhibitor of reuptake of norepinephrine and serotonin).
More serious side effects of tramadol hydrochloride 50 mg tablets can include respiratory depression.
5.2 Life-Threatening Respiratory Depression (serious, life-threatening, or fatal respiratory depression); 5.6 pediatric life-threatening respiratory depression/death.
More serious side effects of tramadol hydrochloride 50 mg tablets can include seizures.
5.10 Increased Risk of Seizures (seizures reported within recommended dosage range).
Unsupported Statements
Tramadol hydrochloride 50 mg tablets are an oral medication used for the management of moderate to moderately severe pain.
Provided label excerpt is for Tramadol Hydrochloride Extended-Release Capsules and indicates management of severe and persistent pain requiring an opioid analgesic; the claim specifies '50 mg tablets' and 'moderate to moderately severe pain,' which is not supported by the provided label excerpts.
Tramadol hydrochloride is a centrally acting synthetic opioid analgesic.
The provided label excerpts identify it as an opioid agonist but do not support 'centrally acting' or 'synthetic' characterization in the included text.
The recommended starting dosage for tramadol hydrochloride 50 mg tablets is typically 50 to 100 mg every 4 to 6 hours as needed for pain.
The provided label excerpt is for extended-release capsules administered once daily; no 'every 4 to 6 hours as needed' regimen is supported in the supplied label excerpts.
The dosage of tramadol hydrochloride 50 mg tablets may be adjusted by a healthcare provider based on the severity of pain and the patient's response.
No specific dose-adjustment guidance is provided in the supplied label excerpts (beyond maximum daily dose and administration instructions).
Patients should not exceed the maximum daily dose recommended by a doctor.
While a maximum daily dose is present in the label excerpt (do not exceed 300 mg/day), the claim is generic ('recommended by a doctor') and does not cite the label-specific limit.
Common side effects of tramadol hydrochloride 50 mg tablets can include dizziness.
The provided adverse-reactions excerpts do not list dizziness as a common side effect.
Common side effects of tramadol hydrochloride 50 mg tablets can include nausea.
The provided adverse-reactions excerpts do not list nausea as a common side effect.
Common side effects of tramadol hydrochloride 50 mg tablets can include constipation.
Constipation is mentioned in pharmacodynamics examples (reduction in motility), but the claim specifies 'common side effects' wording not supported by the provided adverse reaction excerpt.
Common side effects of tramadol hydrochloride 50 mg tablets can include headache.
The provided adverse-reactions excerpts do not list headache as a common side effect.
Common side effects of tramadol hydrochloride 50 mg tablets can include somnolence (sleepiness).
The provided adverse-reactions excerpts do not list somnolence as a common side effect.
More serious side effects of tramadol hydrochloride 50 mg tablets can include confusion.
Confusion is not supported in the provided adverse reaction excerpts.
Patients should report persistent or bothersome side effects to their healthcare provider.
No such counseling statement is present in the provided label excerpts.
Generic versions of tramadol hydrochloride 50 mg tablets are available.
No patent/generic availability statements are provided in the supplied label excerpts.
Other manufacturers can produce and market generic versions once a brand-name drug's patent expires and regulatory approval is granted.
No such regulatory/patent/generic-production statements are provided in the supplied label excerpts.
Generic versions of tramadol hydrochloride 50 mg tablets are typically less expensive.
No pricing statements are provided in the supplied label excerpts.
Tramadol hydrochloride 50 mg tablets are regulated by national health authorities.
Not present in the provided label excerpts.
In the United States, tramadol hydrochloride 50 mg tablets are regulated by the Food and Drug Administration (FDA).
Not present in the provided label excerpts.
In Europe, tramadol hydrochloride 50 mg tablets are regulated by the European Medicines Agency (EMA).
Not present in the provided label excerpts.
National health authorities review safety and efficacy data before approving medications.
Not present in the provided label excerpts.
National health authorities monitor medications post-market.
Not present in the provided label excerpts.
Contradictions
High
AI Statement
The recommended starting dosage for tramadol hydrochloride 50 mg tablets is typically 50 to 100 mg every 4 to 6 hours as needed for pain.
Label Reference
2 DOSAGE AND ADMINISTRATION: 'Tramadol Hydrochloride Extended-Release Capsules are administered orally once daily.'
Moderate
AI Statement
Tramadol hydrochloride 50 mg tablets are an oral medication used for the management of moderate to moderately severe pain.
Label Reference
1 INDICATIONS AND USAGE: 'indicated for the management of severe and persistent pain that requires an opioid analgesic...'
Important Omissions
Extended-release specific administration instructions (swallow whole; break/chew/split/dissolve causes uncontrolled delivery) and 'do not use concomitantly with other tramadol products.'
Importance:
High
Label-specific maximum dose instruction for this formulation: 'Do not administer ... at a dose exceeding 300 mg per day.'
Importance:
Moderate
Key contraindications (e.g., children <12 years; post-tonsillectomy/adenoidectomy in <18 years; MAOI use within 14 days; hypersensitivity; significant respiratory depression/acute severe asthma).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Major mismatch in dosing/administration (claim of immediate-release-like 'every 4 to 6 hours as needed' versus label's once-daily extended-release administration) plus omission of formulation-specific swallowing and maximum-dose instructions and major contraindications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Conflicts with extended-release prescribing: dosing schedule and formulation details are inconsistent with label, and multiple label-critical administration/contraindication elements are omitted.
Suggested Improvement
Use the label’s exact product/formulation (extended-release capsules), state once-daily oral administration and maximum daily dose (≤300 mg/day), include 'swallow whole' and 'do not break/chew/split/dissolve,' and accurately summarize the specific contraindications (including pediatric restrictions and MAOI timing).